Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 08/27/14 → 02/26/20 |
Funding
- Merck Sharp and Dohme Limited Liability Corporation: $141,265.00
A Phase III open-label clinical trial to study the efficacy and safety of the combination regimen of MK-5172/MK-8742 in treatment-naive subjects with chronic HCV GT1, GT4, GT5, and GT6 infection who are on opiate substitution therapy
- Talal, Andrew (PI)
- Martinez, Anthony (CoI)
Project: Research